Welcome to our dedicated page for PharmChem news (Ticker: PCHM), a resource for investors and traders seeking the latest updates and insights on PharmChem stock.
PharmChem, Inc. reports corporate and governance developments for an OTC-traded operating company whose business centers on sweat patches used to detect drugs of abuse. News about PCHM includes strategic-review activity, shareholder voting matters, tender-offer and capital-structure actions, and board-level governance disputes. Company updates also reference operating risks tied to laboratory screening arrangements, reagent supply, FDA 510(k) clearance considerations, Unique Device Identification requirements, and liability insurance obligations for its drug-testing product business.
PharmChem (OTC: PCHM) announced that shareholders have approved its acquisition by Alcohol Monitoring Systems, Inc. at a special meeting held on August 27, 2025. According to the agreement terms, PharmChem shareholders will receive $3.75 per share in cash consideration.
The transaction is expected to be finalized at the close of business on August 28, 2025. The company has provided contact information for shareholders with specific questions regarding the acquisition.
PharmChem (OTC: PCHM), a leading provider of sweat patches for drug abuse detection, has announced its acquisition by Alcohol Monitoring Systems, Inc. for $3.75 per share in cash. The deal represents a 22% premium over PharmChem's closing price of $3.07 on January 31, 2025.
The transaction, unanimously approved by PharmChem's board of directors, has already secured support agreements for 52% of outstanding shares. The acquisition is expected to close by the end of Q3 2025, subject to shareholder approval and customary closing conditions. This strategic move aims to expand Alcohol Monitoring Systems' capabilities into drug testing while complementing their existing alcohol and location monitoring technologies portfolio.
PharmChem (OTC: PCHM), a leading provider of sweat patches for drug abuse detection, announced on February 3, 2025, that its Board of Directors has initiated an exploration of strategic alternatives. The company will consider various options including acquisitions, potential sale, merger, or a debt-financed special dividend.
The Board believes PharmChem would be more valuable as part of a larger company and better positioned to serve customers. The company has established a data room for interested parties but has not retained a financial advisor, citing the Board's sufficient experience to guide the process.
The company emphasized there is no guarantee this review will result in any transaction or strategic outcome, and no specific timeline has been set. Further announcements will only be made if the Board approves a specific transaction or if disclosure is legally required.
PharmChem, Inc. (OTC: PCHM) has announced a modified Dutch auction tender offer to repurchase up to $5 million of its common stock at prices between $3.25 and $3.75 per share. Shareholders can tender shares within this price range before the offer expires on May 31, 2022. The board believes this method provides an efficient opportunity for shareholders to sell their shares. However, the offer is subject to certain conditions and does not require a minimum number of shares to be tendered.
PharmChem has responded to a proxy battle initiated by Cedar Creek Partners, urging shareholders to vote for the white proxy card and disregard the opposition's blue card. The company asserts that its current management and board are essential for continued success, citing substantial growth in sales from $769,000 to $6.7 million and an increase in pre-tax income from a loss of $128,000 to $2.1 million since 2005. The opposition's inexperience and intentions to replace key executives could jeopardize the company's progress and relationships within the industry.